NOW ENROLLING
Research Studies for ages 18-75 to help evaluate investigational T2D medications aimed at lowering HbA1c levels.
About Our Studies
These clinical research studies are evaluating investigational T2D medications for ages 18-75 with type 2 diabetes. The studies are assessing how well these potential new medicines lower blood sugar and how safe they are when added to participants’ existing diabetes treatment.
Participation lasts approximately 49-56 weeks and includes study-related care, health assessments, and regular monitoring by a clinical team. Eligible participants may include ages 18-75 who have HbA1c levels of 7.0%–10.5%.
Participants May Receive:
- Study-related care and monitoring at no cost
- Care and attention from a dedicated clinical research team
- Study-related tests and evaluations provided at no charge
- Compensation for time and travel may be available
- No health insurance required for participation
- All study related visits and procedures are scheduled in advance.
You May Qualify If You:
- Are 18-75 years of age
- Have been diagnosed with type 2 diabetes
- Have an HbA1c level of 7.5%–10.5%
- Are currently taking Ozempic (semaglutide injection) OR have not recently tried any GLP-1
- Are willing to attend scheduled study visits and follow study procedures
About Type 2 Diabetes
Type 2 diabetes is a chronic condition in which the body either doesn’t produce enough insulin or doesn’t use insulin effectively, leading to high blood sugar levels. It is one of the most common chronic diseases worldwide, affecting millions of people of all ages and backgrounds.
Managing type 2 diabetes typically involves a combination of lifestyle changes — such as healthy eating, regular physical activity, and weight management — along with medications to help control blood sugar levels. Common medicines include metformin, SGLT2 inhibitors, and GLP-1 receptor agonists. Despite these options, many people with type 2 diabetes struggle to reach their blood sugar targets, which is why new treatment options are being studied.
To see if you are eligible, please complete the form to get in touch with the study team.
Your privacy is important to us. By completing the following pre-screener you agree to our Privacy Policy and Terms of Use, and agree that we may retain the personal information you provide and share it with personnel involved in the study, or otherwise as described in the Privacy Policy, and we or our affiliates may contact you by phone using automated technology or pre-recorded voicemail or other means including but not limited to text messages (standard messaging rates may apply) regarding research studies.